On March, 14 WallStreet anticipated MyoKardia, Inc. (NASDAQ:MYOK)’s earnings release, Zacks reports. Analysts forecast $-0.46 earnings per share, which is $0.25 down or 119.05 % from 2018’s $-0.21 earnings per share. Wall Street forecasts 17.95 % negative EPS growth as of March, 14. MYOK is reaching $49.18 during the last trading session, after increased 2.99%.MyoKardia, Inc. is uptrending after having risen 54.66% since March 4, 2018. MYOK has 591,554 volume or 31.97% up from normal. MYOK outperformed the S&P500 by 54.66%.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases.The company has $1.98 billion market cap. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy .Last it reported negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

For more MyoKardia, Inc. (NASDAQ:MYOK) news announced briefly go to: Nasdaq.com, Seekingalpha.com, Seekingalpha.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “MyoKardia (MYOK) Reports Q2 Loss, Tops Revenue Estimates – Nasdaq” announced on August 08, 2018, “Nomura bearish on Xencor in premarket analyst action – Seeking Alpha” on February 22, 2019, “MyoKardia down 1% premarket on early-stage MYK-491 data – Seeking Alpha” with a publish date: December 11, 2018, “MyoKardia to Host R&D Day on October 30, 2018 – GlobeNewswire” and the last “Wednesday 1/9 Insider Buying Report: MYOK, FSD – Nasdaq” with publication date: January 09, 2019.